Across TCGA pan-cancer cohorts, ATL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATL3 data layer compared with 18 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM, LSCC, and HNSC are the cancer types where ATL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.608	0.820	<.001	20	view →
LSCC	OS	Tertile	II,III,IV	0.525	0.945	.007	20	view →
HNSC	DFS	Quartile	II,III,IV	0.988	0.860	.025	10	view →
CCRCC	OS	Quartile	All	0.580	0.974	.042	6	view →
LUAD	OS	Median	III,IV	0.265	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ATL3 tumor-vs-normal RNA expression · all ATL3 data types